Showing 1,081 - 1,100 results of 226,558 for search '(( 50 ((ng decrease) OR (we decrease)) ) OR ( 10 ((a decrease) OR (nn decrease)) ))', query time: 1.35s Refine Results
  1. 1081

    Chloro Half-Sandwich Osmium(II) Complexes:  Influence of Chelated N,N-Ligands on Hydrolysis, Guanine Binding, and Cytotoxicity by Anna F. A. Peacock (1297842)

    Published 2007
    “…Relatively little is known about the kinetics or the pharmacological potential of organometallic complexes of osmium compared to its lighter congeners, iron and ruthenium. We report the synthesis of seven new complexes, [(η<sup>6</sup>-arene)Os(NN)Cl]<sup>+</sup>, containing different bidentate nitrogen (N,N) chelators, and a dichlorido complex, [(η<sup>6</sup>-arene)Os(N)Cl<sub>2</sub>]. …”
  2. 1082

    Chloro Half-Sandwich Osmium(II) Complexes:  Influence of Chelated N,N-Ligands on Hydrolysis, Guanine Binding, and Cytotoxicity by Anna F. A. Peacock (1297842)

    Published 2007
    “…Relatively little is known about the kinetics or the pharmacological potential of organometallic complexes of osmium compared to its lighter congeners, iron and ruthenium. We report the synthesis of seven new complexes, [(η<sup>6</sup>-arene)Os(NN)Cl]<sup>+</sup>, containing different bidentate nitrogen (N,N) chelators, and a dichlorido complex, [(η<sup>6</sup>-arene)Os(N)Cl<sub>2</sub>]. …”
  3. 1083

    Chloro Half-Sandwich Osmium(II) Complexes:  Influence of Chelated N,N-Ligands on Hydrolysis, Guanine Binding, and Cytotoxicity by Anna F. A. Peacock (1297842)

    Published 2007
    “…Relatively little is known about the kinetics or the pharmacological potential of organometallic complexes of osmium compared to its lighter congeners, iron and ruthenium. We report the synthesis of seven new complexes, [(η<sup>6</sup>-arene)Os(NN)Cl]<sup>+</sup>, containing different bidentate nitrogen (N,N) chelators, and a dichlorido complex, [(η<sup>6</sup>-arene)Os(N)Cl<sub>2</sub>]. …”
  4. 1084

    Chloro Half-Sandwich Osmium(II) Complexes:  Influence of Chelated N,N-Ligands on Hydrolysis, Guanine Binding, and Cytotoxicity by Anna F. A. Peacock (1297842)

    Published 2007
    “…Relatively little is known about the kinetics or the pharmacological potential of organometallic complexes of osmium compared to its lighter congeners, iron and ruthenium. We report the synthesis of seven new complexes, [(η<sup>6</sup>-arene)Os(NN)Cl]<sup>+</sup>, containing different bidentate nitrogen (N,N) chelators, and a dichlorido complex, [(η<sup>6</sup>-arene)Os(N)Cl<sub>2</sub>]. …”
  5. 1085

    Rhodomyrtone decreases expression of inflammatory transcripts by TNF-α+IL-17A stimulated in skin organ cultures. by Julalak Chorachoo (5855852)

    Published 2018
    “…<p>Skin biopsies were pre-treated with 400 ng/ml rhodomyrtone 6 h before stimulation with 10 ng/ml TNF-α and 20 ng/ml IL-17A. Rhodomyrtone treatment decreases production of <i>DEFB4</i>, <i>IL1B</i>, <i>IL17C</i>, <i>IL36G</i>, <i>LCN2</i>, <i>PI3</i>, <i>S100A7</i>, and <i>S100A8</i> transcripts as measured by qRT-PCR at 72 h. …”
  6. 1086
  7. 1087

    JNK inhibitor AS601245 decreased levels of Bim and CC3 proteins and reduced neuronal apoptosis and brain infarct volume in P7 rat after HI. by Deyuan Li (769599)

    Published 2015
    “…The infarct volume in the AS601245-treated brain was decreased by 58% compared with the DMSO controls (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132998#pone.0132998.g004" target="_blank">Fig 4I</a>).…”
  8. 1088
  9. 1089
  10. 1090
  11. 1091
  12. 1092
  13. 1093
  14. 1094
  15. 1095
  16. 1096
  17. 1097

    Inhibition of ADAM10 affects Notch targeted Hes5 and Gli genes in the ventral spinal cord (A–H) and in vitro cultured cell system (I–M). by Xin Yan (17064)

    Published 2014
    “…The ADAM10-mo transfected cells are green and the left side serves as a control. …”
  18. 1098
  19. 1099
  20. 1100

    Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells by Tadeja Kuret (5059433)

    Published 2018
    “…Both anti-SAA and anti-SAA1α exhibited heterogeneous to high avidity and reached peak levels between 41–50 years, then diminished with age in the oldest group (51–67 years). …”